Clinical Trial Update: Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant [Phase 2]

View source ↗

Summary

A Phase 2 study of midostaurin in older patients with AML with gene mutations after transplant has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia in Remission
• Acute Myeloid Leukemia with Gene Mutations

Drugs mentioned

• Midostaurin (midostaurin)

Snippet

Sponsor: Stanford University | Conditions: Acute Myeloid Leukemia With Gene Mutations, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Status: WITHDRAWN